![Surface Decomposition of Doped PrBaMn2O5+δ Induced by In Situ Nanoparticle Exsolution: Quantitative Characterization and Catalytic Effect in Methane Dry Reforming Reaction | Chemistry of Materials Surface Decomposition of Doped PrBaMn2O5+δ Induced by In Situ Nanoparticle Exsolution: Quantitative Characterization and Catalytic Effect in Methane Dry Reforming Reaction | Chemistry of Materials](https://pubs.acs.org/cms/10.1021/acs.chemmater.2c02488/asset/images/medium/cm2c02488_0004.gif)
Surface Decomposition of Doped PrBaMn2O5+δ Induced by In Situ Nanoparticle Exsolution: Quantitative Characterization and Catalytic Effect in Methane Dry Reforming Reaction | Chemistry of Materials
![PDF) The Reuse of Archaeological Data: Grand Challenges and New Approaches to Southern Levantine Mortuary Archaeology | Sara Mura - Academia.edu PDF) The Reuse of Archaeological Data: Grand Challenges and New Approaches to Southern Levantine Mortuary Archaeology | Sara Mura - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/65371064/mini_magick20210108-17760-iqzory.png?1610104424)
PDF) The Reuse of Archaeological Data: Grand Challenges and New Approaches to Southern Levantine Mortuary Archaeology | Sara Mura - Academia.edu
![PDF) Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): An open-label, randomised, phase 3 trial PDF) Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): An open-label, randomised, phase 3 trial](https://i1.rgstatic.net/publication/276358091_Efficacy_of_neoadjuvant_bevacizumab_added_to_docetaxel_followed_by_fluorouracil_epirubicin_and_cyclophosphamide_for_women_with_HER2-negative_early_breast_cancer_ARTemis_An_open-label_randomised_phase_/links/561ebf4f08aec7945a26ff47/largepreview.png)
PDF) Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): An open-label, randomised, phase 3 trial
![PDF) Multi-Stakeholder Governance for Effectively Sharing Social Responsibility (Social Contracts, Deliberative Democracy and Endogenous Conformity) | Lorenzo Sacconi - Academia.edu PDF) Multi-Stakeholder Governance for Effectively Sharing Social Responsibility (Social Contracts, Deliberative Democracy and Endogenous Conformity) | Lorenzo Sacconi - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/50358212/mini_magick20190129-14857-ne7ops.png?1548776708)
PDF) Multi-Stakeholder Governance for Effectively Sharing Social Responsibility (Social Contracts, Deliberative Democracy and Endogenous Conformity) | Lorenzo Sacconi - Academia.edu
![PDF) In step with contemporary trends-stem-celltherapy as a key driver of regenerative orthopedics at the Clinical Center of Vojvodina - preliminary data for the treatment of knee osteoarthritis and osteochondral lesions PDF) In step with contemporary trends-stem-celltherapy as a key driver of regenerative orthopedics at the Clinical Center of Vojvodina - preliminary data for the treatment of knee osteoarthritis and osteochondral lesions](https://i1.rgstatic.net/publication/312646232_In_step_with_contemporary_trends-stem-celltherapy_as_a_key_driver_of_regenerative_orthopedics_at_the_Clinical_Center_of_Vojvodina_-_preliminary_data_for_the_treatment_of_knee_osteoarthritis_and_osteoc/links/58b51b3192851cf7ae941a54/largepreview.png)
PDF) In step with contemporary trends-stem-celltherapy as a key driver of regenerative orthopedics at the Clinical Center of Vojvodina - preliminary data for the treatment of knee osteoarthritis and osteochondral lesions
![Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2) - The Lancet Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2) - The Lancet](https://www.thelancet.com/cms/attachment/6e7c64fd-e6a8-47d8-ac46-cb9c37ef8dd7/gr1_lrg.jpg)